Key Slides on Emerging Insights on Adverse Events During ART and Implications for Treatment

Gain expert insight on the impact of emerging ART safety and tolerability data on ART initiation and switch strategies.
Joseph J. Eron, Jr., MD
Darcy Wooten, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 571 KB
Released: May 11, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Dr Milosz Parczewski and Clinical Care Options (CCO): Update from EACS 2021 on the HIV care continuum in Eastern Europe

Milosz Parczewski, MD, PhD Released: December 3, 2021

Expert recap of new data on rapid ART with BIC/FTC/TAF from EACS 2021, from Dr Monica Gandhi at Ward 86 and Clinical Care Options (CCO)

Monica Gandhi, MD, MPH Released: December 1, 2021

Commentary from Dr Juan Luis Mosqueda Gomez on the latest findings from the IMEA 055 FAST study presented at EACS 2021 and how test-and-treat strategies could improve patient care and virologic suppression in Mexico, from Clinical Care Options (CCO)

Juan Luis Mosqueda Gomez, MD, MSc Released: December 1, 2021

Commentary from Dr Yan Zhao on the latest findings from EACS 2021 highlighting the unique challenges of older people living with HIV, from Clinical Care Options (CCO)

person default Yan Zhao, MD Released: November 30, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue